Editas Medicine to Present Pre-clinical Data Demonstrating P

CAMBRIDGE, Mass., April 22, 2024 -- Editas Medicine, Inc. , a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral...

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , American , Lindac Burkly , , Broad Institute Cas , Harvard University Cas , Editas Medicine Inc , Broad Institute , Exchange Commission , Meeting Of The American Society Gene , Nasdaq , Annual Meeting , American Society , Cell Therapy , Executive Vice President , Chief Scientific Officer , Editas Medicine , Based Delivery , Potential Treatment , Vivo Gene Therapies , Abstract Number , Chemically Modified Ascas , Thursday Posters , Gene Disruption , Metagenomic Discovery , Novel Recombinase Proteins , Friday Posters , Targeted Gene Insertion , Harvard University , Private Securities Litigation Reform Act , Annual Report , Markets ,